The verdict: Fujifilm to take its $2B CDMO investment to North Carolina

Fujifilm Corporation has selected Holly Springs, NC as the location for its new large-scale cell culture production site in the US. The $2 billion investment—originally announced this past January—will establish the largest end-to-end cell culture biopharmaceutical contract development and manufacturing organization (CDMO) facility in North America, the company says. It is scheduled to begin operations in the spring of 2025, and expected to create 725 jobs in the area by the end of 2028.

Fujifilm Diosynth Biotechnologies, a Fujifilm subsidiary with locations in the US, UK and Denmark, will be in charge of the new facility.

A thorough evaluation process was utilized in order to choose Holly Springs for the new location. The city was selected for its strong pool of technical talent, local resources and partners with the right competencies, clean energy resources, and sustainability for future growth. Fujifilm also owns a facility in nearby Morrisville, NC.